Luye Pharma Group Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Denosumab NCT05853354 |
P3 | Active, not recruiting | Osteoporosis, Postmenopausal | 392 | 2025-07-30 |
| LPM3770164 sustained release tablet 5 mg NCT06731868 |
P1/2 | Recruiting | Tardive Dyskinesia (TD) | 120 | 2025-10-31 |
| LY01021 NCT07236476 |
P2 | Active, not recruiting | Assisted Reproduction | 90 | 2025-12-31 |
| Lurbinectedin NCT06496048 |
P3 | Recruiting | Relapsed Small Cell Lung Cancer | 180 | 2027-12-31 |
| LY03020 NCT07396870 |
P2 | Not yet recruiting | Schizophrenia | 160 | 2027-12-31 |
| Irinotecan hydrochloride liposome Injection NCT06128837 |
P3 | Recruiting | Relapsed Small Cell Lung Cancer | 686 | 2028-06 |
| LPM6690176 NCT07391566 |
P1/2 | Not yet recruiting | Metastatic Colorectal Cancer (mCRC) | 99 | 2028-12-31 |